LOS ANGELES, Feb. 9, 2016 /PRNewswire/ -- Med-X, Inc. (Med-X) today announced that their Regulation A+ (Reg A+) equity crowdfunding campaign - one of the first of its kind for the medical cannabis industry - is now accepting investment funding beginning at the $420 level or 700 shares. In approximately an 8 week period Med-X was able to receive $3.6 million in reservations from over 1100 prospective investors for their Reg A+ campaign on StartEngine.com.
"This offering presents a tremendous opportunity for American investors seeking to get in on the ground floor of the burgeoning cannabis industry -- without the normal accreditation requirements for start-up companies," said Matthew Mills, COO of Med-X. "Virtually any American who earns an annual income of $4,200 and is age 18 or older can participate. Keep in mind that you're not simply investing in the cannabis industry; you're investing in our green medicine mission. What's more, the successful launch of Med-X is 100% due to the opportunity brought to us by the JOBS Act of 2012. We are proof that if you are willing to sacrifice the time and effort to do it right, following all the rules of crowdfunding and raising capital is a worthwhile endeavor."
In addition to the success of their equity crowdfunding campaign, Med-X's flagship product, Nature-Cide All Purpose Insecticide, has continued to gain a following. This has prompted Med-X to prepare for the release of their second natural product in Q3 and Q4 of 2016, a patent-pending proprietary natural soil blend that encompasses natural insecticidal properties. "Comprised of 100% various natural proven pest-preventing plant matter and superior cultivation ingredients, this soil gives cultivators one natural proven brand for all their growing medium and pest prevention needs for cannabis cultivation," states Mills.
By using the insecticidal soil along with Nature-Cide products, Med-X has been cultivating and protecting cannabis plants throughout multiple cultivation cycles in the Med-X Lab. By providing these all-natural solutions, Med-X is on track to become the industry leader in integrated pest-management solutions for cannabis cultivation, thus creating a new standard for organic medicine.
An In-depth Look at the Cannabis Industry; How Anyone Can Invest
The $5.4 billion legal cannabis industry is poised to reach $6.7 billion by 2016 and $21 billion by 2020, according to industry analyst ArcView Market Research. To learn more about the future of this rapidly growing industry -- including important innovations in cultivation, research and development -- and Med-X's current investment opportunity, visit https://www.startengine.com/startup/med-x.
ABOUT MED-X, INC.
Med-X, Inc. is a Nevada corporation formed in February 2014 to support the fast-paced emerging cannabis industry through such activities as compound identification and extraction of the identified cannabidiol (CBD) compounds for the present medical industry demand. The company's digital magazine, The Marijuana Times, publishes quality media content for the medical cannabis community to generate revenue from advertisers as well as sell industry related merchandise to consumers. The company is ready to bring various products to market in the cannabis, agricultural and ancillary services industries through manufacturing partnerships. For more information regarding Med-X, Inc., please visit www.medx-rx.com, email email@example.com or call 818-349-2870.
DISCLAIMER AND FORWARD-LOOKING STATEMENTS
The securities offered hereby are highly speculative. Investing in shares of MED-X, INC. involves significant risks. This investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that an investment could be illiquid for an indefinite period of time. No public market currently exists for the securities and if a public market develops following this offering it may not continue. You should read the offering circular before making any investment.
This release may contain forward-looking statements regarding projected business performance, operating results, financial condition and other aspects of the company, expressed by such language as "expected," "anticipated," "projected" and "forecasted." Please be advised that such statements are estimates only and there is no assurance that the results stated or implied by forward-looking statements will actually be realized by the company. Forward-looking statements may be based on management assumptions that prove to be wrong. The company and its business are subject to substantial risks and potential events beyond its control that would cause material differences between predicted results and actual results, including the company incurring operating losses and experiencing unexpected material adverse events.
SOURCE Med-X, Inc.